Heart Rate Variability During Acute Diverticulitis

Overview

The purpose of this study is to investigate heart rate variability during Acute uncomplicated diverticulitis by ECG-monitor (Holter), the investigators hypothesis is the inflammation causes a decrease of High Frequency(HF)-power component of heart rate variability and this correlates with sleep quality and daytime fatigue.

Full Title of Study: “Heart Rate Variability in the Course of Acute Uncomplicated Diverticulitis”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: November 2013

Detailed Description

An increasing number of studies have shown that circadian variation in the excretion of hormones, the sleep-wake cycle, the core body temperature, the tone of the autonomic nervous system and the activity rhythm are important both in health and disease processes. The investigators are interested in investigating the heart rate variability (HRV) during an acute surgical non-inflammatory condition, and to exam whether there are correlations between: HRV and sleep stages, HRV and cytokine levels in blood and HRV and subjective fatigue. Following methods will be applied Device: Holter monitor – Medilog AR12 (Oxford Instruments, Oxford, England) Other: Karolinska Sleepiness Scale Other: Physical Fatigue Scale Device: Polysomnograph – Embla Titanium (Natus Medical Incorporated, USA) Procedure: Plasma cytokines (IL-2, IL-6 and TNF(tumor necrosis factor)-alfa) Procedure: Plasma CRP(C reactive protein) and leukocytes

Arms, Groups and Cohorts

  • acute uncomplicated diverticulitis
    • CT-verified acute uncomplicated diverticulitis managed by antibiotics

Clinical Trial Outcome Measures

Primary Measures

  • Heart-rate variability changes during the acute uncomplicated diverticulitis compared to the baseline levels at 30th night where the condition has been cured
    • Time Frame: 1st, 2nd and 30th night following the admission
    • Heart-rate variability measured by Holter monitor and a following analysis of frequency and time domain parameters.

Secondary Measures

  • changes in plasma cytokine levels during the acute uncomplicated diverticulitis from the baseline levels at 30th day (remission)
    • Time Frame: 1st, 2nd and 30th days following the admission
    • the blood sample is taken at night before sleep time. the cytokines are measured with ELISA-kit
  • change in Sleep data during the acute diverticulitis from baseline Sleep data at remission (30th day)
    • Time Frame: 1st, 2nd and 30th days following the admission
    • Sleep data is measured by Polysomnography and sleep is categorized into sleep stages (awake, stage 1, 2, REM-sleep and SWS-sleep)

Participating in This Clinical Trial

Inclusion Criteria

  • CT-verified diverticulitis patients managed by antibiotic treatment at Herlev Hospital – Pain and fever occurred less than 72 hours prior to the admission – ASA (American Society of Anesthesiologists) score I to III Exclusion Criteria:

  • Surgical intervention needed – Complicated diverticulitis – Complications in relation to diverticulitis – Pain and fever occurred more than 72 hours prior to the admission – In anticoagulant treatment and heart rate control treatment – Known Autoimmune disease – Known medically treated sleep-disorder (insomnia, restless legs etc.) and sleep apnea – Shift-work or jetlag – Daily use of opioid, psychopharmaca, opioids or anxiolytics (including Hypnotics) – Known psychiatry conditions in treatment with psychopharmaca – Daily alcohol intake of more than 5 units or drug abuse – Missing written consent – Diabetes Mellitus – Predicted bad compliance – Pregnant or breast-feeding – Urine or fecal incontinence – Severe kidney disease – Current cancer

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Herlev Hospital
  • Collaborator
    • Lundbeck Foundation
  • Provider of Information About this Clinical Study
    • Principal Investigator: Ismail Gögenür, Senior resident and D.Sc. – Herlev Hospital
  • Overall Official(s)
    • Ismail Gögenur, M.D., Principal Investigator, University of Copenhagen, Herlev Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.